Skip to content

Educational reference only. Not medical advice, diagnosis, or treatment, and not dosing, injection, or purchasing guidance.Medical disclaimer

MOTS-c

These sentences are taken from FDA’s compounding-risk page and, where noted, the July 2026 advisory-committee agenda. They are not a finding that a substance works.

  • FDA spells the withdrawn-nomination entry “MOTs-C.” It says compounded drugs containing it may pose a significant immunogenicity risk for certain routes, that characterization may be complex, and that FDA has not identified human exposure data for any route.
  • The 23 July 2026 agenda uses both “MOTs-C” and “MOTS-c” and says the committee would discuss the free base and the acetate for the 503A bulks list. Uses FDA says it evaluated are obesity and osteoporosis. No vote is reported here.

Legal effect beyond the words on those pages is not interpreted. No animal or human study is summarized, because none was opened.

This page does not give doses, titration schedules, injection or implantation technique, preparation steps, or places to purchase a product.

Page record

  • Type: Compound
  • Domain: peptides
  • Evidence: Not rated
  • Status: reviewed
  • Last reviewed: 2026-11-20

Sources

Referenced by

A link from another wiki page is not evidence. Facts should point at the sources above.